ReviewNanomedicine (London, England)2025
A drug delivery perspective on nanotechnology-based topical therapeutics for inflammatory skin diseases.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Physicochemical characterization and optimization of Tulsi-mediated silver nanocomposites with enhanced insecticidal activity againstRSC advances · 2026Article
- Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics.Medical sciences (Basel, Switzerland) · 2026Review
- Anti-inflammatory role of metal and metal oxide nanoparticles: a review of toxicity, green synthesis, and immunomodulatory mechanisms.Inflammopharmacology · 2026Review
- Polymeric Nanogels for Skin Applications.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory skin diseases are chronic conditions that significantly affect patients' skin health and quality of life. Traditional treatments, including systemic immunosuppressants and topical therapies, often face limitations such as low efficacy, inadequate skin penetration, and severe side effects. Nanotechnology has emerged as a promising solution to tackle these challenges by providing innovative drug delivery systems that not only enhance therapeutic precision but also reduce systemic exposure. This review highlights the technological innovations and pre-clinical potential of nanotechnology-based therapies in managing inflammatory skin diseases, emphasizing their advantages over conventional treatments and their ability to overcome existing therapeutic limitations. Drug delivery nanosystems like lipid, polymeric, and metallic nanocarriers can be designed to penetrate the skin barrier and deliver drugs directly to the affected tissues. These nanocarriers improve drug stability, bioavailability, and retention in target areas while minimizing adverse effects. Furthermore, nanoparticles can be functionalized with bioadhesive molecules (e.g. hyaluronic acid) to achieve targeted and sustained drug release. In preclinical studies, such advanced formulations have demonstrated the potential to modulate immune responses and reduce inflammation by delivering therapeutics in a controlled and localized manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.